4 Comments
User's avatar
Joe | Goldman Won't Cover This's avatar

I particularly liked the long-term sector specific performance and the breakdown of what to look for in each sector.

I am surprised that Healthcare looks like it doesn't have much volatility over the ten years, given that most had a huge COVID spike and then a big sell-off afterwards.

JB Peter's avatar

As beginners, we always look for good deals, and value stocks always seem like that, but the moat is the real answer.

Big pharma, being a big percentage of healthcare, is “uncorrelated”. A company follow a cycle of low PE, low earnings, bigger PE and EPS, rinse and repeat. But every big pharma stock will do it on a different timeframe.

That’s why I don’t like much Pharma ETFs.

Joe | Goldman Won't Cover This's avatar

Ah yeah that makes sense. I always forget about pharma, as I exclude it from my investing universe.

JB Peter's avatar

I usually do as well, except for GLP1 (Eli Lilly and Novo) as it's easier to understand and a game changer for our societies.